The New England Journal of Medicine has published an article concerning Cologuard the new test developed by our client Exact Sciences.
It shows that in a 10,500 82 site nationwide study that this non-invasive test found 92% of cancer and more than half of the pre-cancer larger than 2 centimeters.
On March 26, Cologuard will be reviewed by an Advisory Committee of the FDA.
Congratulations to Kevin Conroy and his team!